Latest news about Dhanvantri Jeevan Rekha
Dhanvantri Jeevan Rekha
24.95
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-3.03%
6M+9.43%
1Y-7.59%
5Y0.00%
More news about Dhanvantri Jeevan Rekha
17Apr 26
Dhanvantri Jeevan Rekha Limited Submits SEBI Compliance Certificate for Q4 FY26
Dhanvantri Jeevan Rekha Limited filed its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26 with BSE Limited on 17th April 2026. The certificate, issued by registrar Beetal Financial & Computer Services, confirms proper dematerialization processes during the quarter ended 31st March 2026. Company Secretary Ritika Bhandari submitted the mandatory filing, demonstrating the healthcare company's adherence to regulatory requirements and corporate governance standards.
13Feb 26
Dhanvantri Jeevan Rekha Publishes Q3FY26 Results in Newspapers Under SEBI Compliance
Dhanvantri Jeevan Rekha Limited has published its Q3FY26 financial results in newspapers as required by SEBI regulations, reporting strong revenue growth of 27.54% to Rs 727 lacs and maintaining profitability with net profit of Rs 17 lacs. The company's nine-month performance showed revenue growth but declining profits, with results published in both Hindi and English newspapers for regulatory compliance.
14Nov 25
Dhanvantri Jeevan Rekha Reports Net Loss and Declining Cash Reserves in Q2 FY2026
Dhanvantri Jeevan Rekha Limited (DJRL) reported a net loss of Rs. 7.68 lacs for Q2 FY2026. The company's total income was Rs. 593.00 lacs, while total expenses reached Rs. 607.00 lacs. DJRL experienced a significant cash outflow of Rs. 140.09 lacs, reducing cash reserves from Rs. 254.52 lacs to Rs. 114.43 lacs. The healthcare provider's EPS stood at -0.34, reflecting the impact of the loss on shareholder value. For the half-year, DJRL reported a total income of Rs. 1,151.00 lacs and a net loss of Rs. 8.00 lacs.
13Aug 25
Dhanvantri Jeevan Rekha Reports Mixed Q1 Results with Slight Profit Increase
Dhanvantri Jeevan Rekha Limited, operator of Dhanvantri Hospital, released Q1 FY2026 results. Net sales decreased to Rs 551.00 lakhs from Rs 583.00 lakhs in the previous quarter. Profit increased to Rs 5.00 lakhs from Rs 3.00 lakhs quarter-on-quarter but decreased year-on-year from Rs 16.00 lakhs. Total income stood at Rs 558.00 lakhs with total expenses at Rs 552.00 lakhs. EPS was Rs 0.15. The Board approved these results on August 13, 2025.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Suraksha Diagnostic
Krsnaa Diagnostics
3B BlackBio DX
One Global Service Provider
Health X Platform
1,952.80
(+1.48%)
1,557.90
(-0.81%)
582.50
(-0.51%)
572.75
(-0.17%)
713.00
(-3.90%)
351.50
(-1.08%)
553.70
(-1.13%)
1,410.10
(-1.50%)
536.80
(-1.21%)
292.00
(-0.44%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
